rhigm12b7
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 8, 2008 (NCT00658892)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death 1 ligand 2CROSS-LINKING AGENT
PDCD1LG2 cross-linking agent
- T-lymphocyte activation antigen CD80Supplementation
CD80 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109309 ↗
Also known as
- rhigm12b7
- rhigm12b7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00658892 | Phase 1 | Apr 8, 2008 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1